ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Developing medicines
  • Responding to COVID-19
  • Life Sciences Recovery Roadmap

Life Sciences Recovery Roadmap

The COVID-19 crisis has powerfully demonstrated the strategic importance of the life science sector to the UK’s health, security, and to the economy.

Together with the Association of British HealthTech Industries (ABHI), BioIndustry Association (BIA), British Generic Manufacturers Association (BGMA) and the British In Vitro Diagnostic Association (BIVDA), we have put out a call to action on the UK life sciences industry’s commitment to fighting COVID-19 and supporting NHS patients.

Download Life Sciences Recovery Roadmap.

The Life Sciences industry and charities have played a central role in tackling the COVID-19 pandemic. By creating new partnerships with the Government and NHS the sector has rapidly scaled up UK diagnostic capacity; supported the NHS to deliver care in a period of exceptional patient demand; and are leading the search for vaccinations and treatments to tackle the pandemic.

Positive_Microscope
Research and development
What are pharmaceutical companies doing to tackle COVID-19?
Shortages and supply
What impact will coronavirus have on the medicines supply chain?
Report-Pen
Official information
What Government guidance and advice is available?
Positive_Heart
Supporting our NHS
How are life sciences companies helping the NHS on the ground?
Report
Testing
What is the life sciences sector doing to help increase COVID-19 testing?
Positive_World
Commitment from industry
The Life Sciences Recovery Roadmap
Positive_Messages
Q&A
Coronavirus: Your questions answered

We have also seen the future of healthcare in action.  The scientific and technological revolution of the Life Sciences sector – from the use of AI and machine learning in R&D to the latest manufacturing technologies and new treatment paradigms – bringing real value to solving health challenges through new therapies and vaccines.

The Life Sciences Recovery Roadmap sets out how the sector can work with the Government and the NHS so that the sector is at the heart of the economic recovery and can support the NHS in getting cutting edge healthcare to patients.

This paper was submitted to Government by trade bodies that represent the life sciences and charity research sectors through the Life sciences COVID-19 Response Group, co-Chaired by Lord Bethell and Nadhim Zahawi MP.

The Roadmap provides an overview of the critical issues affecting the sector as we look towards recovery and building a new partnership between the Life sciences sector, Government and NHS. 

The report focuses on six critical areas:

  • Transforming our partnership with the NHS to support delivery of the Long-Term Plan.

  • Developing a comprehensive strategy to improve UK manufacturing capability and supply chain resilience in medicines, medical devices and diagnostics.

  • Powering up the benefits of public and charity spending on medical research and delivering bold policies to incentivise research investment.

  • Transforming the UK’s clinical research processes.

  • Taking an innovative approach to regulation:

  • Accelerating deployment of new and existing treatments and technologies where there are system and patient benefits.

Responding to COVID-19

  • What impact will coronavirus have on the medicines supply chain?
  • What are pharmaceutical companies doing to tackle COVID-19?
  • What Government guidance and advice is available?
  • How are life sciences companies helping the NHS on the ground?
  • What is the life sciences sector doing to help increase COVID-19 testing?
  • Life Sciences Recovery Roadmap
  • Coronavirus: Your questions answered

RELATED LINKS

  • ABPI responds to Government’s coronavirus testing ‘call to arms’
  • Joint statement on COVID-19 testing and diagnostics
  • Responding to COVID-19

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.